Profile data is unavailable for this security.
About the company
SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.
- Revenue in SEK (TTM)0.00
- Net income in SEK-106.27m
- Incorporated2016
- Employees8.00
- LocationSynAct Pharma ABScheelevagen 2LUND 22363SwedenSWE
- Websitehttps://synactpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dicot Pharma AB | 126.00k | -84.00m | 642.99m | 4.00 | -- | 7.12 | -- | 5,103.09 | -0.0459 | -0.0459 | 0.00007 | 0.0449 | 0.001 | 10.68 | 0.0371 | 42,000.00 | -69.50 | -94.78 | -75.43 | -111.46 | -61,341.27 | -32,616.05 | -66,663.49 | -37,576.05 | 8.82 | -- | 0.00 | -- | -88.60 | -47.16 | -30.66 | -- | -- | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -79.73m | 755.05m | 10.00 | -- | 6.28 | -- | -- | -5.92 | -5.92 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.19 | -22.82 | -48.56 | -24.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.24 | -- | -- | -- |
| Cinclus Pharma Holding publ AB | 48.42m | -177.05m | 800.45m | 19.00 | -- | 1.90 | -- | 16.53 | -3.80 | -3.80 | 1.04 | 9.07 | 0.0777 | -- | 15.47 | 3,724,539.00 | -28.43 | -- | -32.01 | -- | -- | -- | -365.65 | -- | -- | -- | 0.0197 | -- | -23.14 | -- | 21.89 | -- | -- | -- |
| Vistin Pharma ASA | 426.86m | 73.26m | 873.96m | 77.00 | 11.93 | 2.98 | 9.35 | 2.05 | 1.76 | 1.76 | 10.26 | 7.05 | 1.12 | 1.87 | 6.20 | -- | 19.20 | 1.65 | 23.64 | 1.99 | 66.40 | 62.28 | 17.16 | 1.88 | 1.16 | -- | 0.063 | -- | -1.45 | 13.56 | 37.62 | -1.03 | 17.32 | -- |
| Orexo AB | 386.40m | -201.10m | 975.37m | 72.00 | -- | 1.98 | -- | 2.52 | -5.80 | 18.42 | 11.15 | 14.22 | 0.4073 | 1.29 | 2.02 | 5,366,667.00 | -21.20 | -28.03 | -29.75 | -42.57 | 89.96 | 83.88 | -52.04 | -74.89 | 3.70 | -3.00 | 0.5005 | -- | -12.46 | -47.69 | 15.63 | -- | -- | -- |
| Arcticzymes Technologies ASA | 96.73m | 7.19m | 1.03bn | 55.00 | 146.82 | 3.32 | 66.53 | 10.65 | 0.1464 | 0.1464 | 1.97 | 6.47 | 0.2967 | 0.295 | 1.91 | 1,874,073.00 | 2.20 | 13.28 | 2.32 | 14.39 | 95.42 | 96.20 | 7.43 | 31.41 | 15.45 | -- | 0.0184 | 0.00 | -12.26 | 18.22 | -56.40 | -- | 53.98 | -- |
| SynAct Pharma AB | 0.00 | -106.27m | 1.04bn | 8.00 | -- | 5.33 | -- | -- | -2.20 | -2.20 | 0.00 | 3.65 | 0.00 | -- | -- | 0.00 | -45.16 | -85.38 | -50.22 | -99.19 | -- | -- | -- | -- | -- | -63.96 | 0.0071 | -- | -- | -- | 61.82 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to SynAct Pharma AB's reporting currency: Swedish Krona SEK
2.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Jan 2026 | 885.32k | 1.66% |
| SEB Funds ABas of 31 Dec 2025 | 333.51k | 0.63% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 209.20k | 0.39% |
| Skandia Investment Management ABas of 28 Nov 2025 | 110.40k | 0.21% |
| Danske Bank A/S (Investment Management)as of 31 Jan 2026 | 3.45k | 0.01% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 1.12k | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
